BerGenBio ASA: New share capital registered

28 May 2024 10:08 CEST

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange
announcement by BerGenBio ASA (the "Company") on 23 May 2024 regarding the
Company's annual general meeting resolving to increase the Company's share
capital by NOK 3.30 by issuance of 33 new shares, each with a nominal value of
NOK 0.10 to ensure that the Company's total number of outstanding shares are
divisible by 100 and thereby facilitate for the reverse share split in the
Company resolved at the same general meeting.

The share capital increases pertaining to the new shares is now registered with
the Norwegian Register of Business Enterprises. After this, the Company's new
registered share capital is NOK 390,871,160 divided into 3,908,711,600 shares,
each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site